切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2026, Vol. 15 ›› Issue (04) : 349 -355. doi: 10.3877/cma.j.issn.2095-3224.2026.04.008

综述

免疫微环境调控直肠癌淋巴结转移的机制及其相关影像学研究进展
王逸敏1,,2, 刘爱连2,,3,,4,()   
  1. 1 610500 成都医学院第一附属医院放射科
    2 116011 大连医科大学附属第一医院放射科
    3 116011 辽宁省超极化磁共振专业技术创新中心
    4 116011 大连市医学影像人工智能技术创新中心
  • 收稿日期:2026-01-19 出版日期:2026-08-25
  • 通信作者: 刘爱连
  • 基金资助:
    成都医学院教育教学改革项目(JG2020037)

Mechanisms of immune microenvironment regulation of lymph node metastasis in rectal cancer and advances in related imaging research

Yimin Wang1,2, Alian Liu2,,3,,4,()   

  1. 1 Department of Radiology, First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, China
    2 Department of Radiology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China
    3 Technology Innovation Center of Hyperpolarized MRI Liaoning Province, Dalian 116011, China
    4 Technology Innovation Center of Artificial Intelligence in Medical Imaging, Dalian 116011, China
  • Received:2026-01-19 Published:2026-08-25
  • Corresponding author: Alian Liu
引用本文:

王逸敏, 刘爱连. 免疫微环境调控直肠癌淋巴结转移的机制及其相关影像学研究进展[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(04): 349-355.

Yimin Wang, Alian Liu. Mechanisms of immune microenvironment regulation of lymph node metastasis in rectal cancer and advances in related imaging research[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2026, 15(04): 349-355.

直肠癌淋巴结转移受肿瘤免疫微环境(TIME)调控,与直肠癌患者的预后息息相关,但目前评估直肠癌患者淋巴结转移的准确性仍有待提升。本文阐述了直肠癌免疫微环境调控淋巴结转移的主要机制,并对以MRI为主的影像学评估直肠癌免疫微环境的研究现状做一总结,以期提高直肠癌患者的术前诊断淋巴结转移的精度,改善患者预后,为个体化诊治提供一些新的思路。

Lymph node metastasis in rectal cancer, which is regulated by the tumor immune microenvironment (TIME), is closely correlated with patient prognosis. Nevertheless, the current accuracy in evaluating lymph node metastasis in rectal cancer patients is still less than satisfactory and needs further enhancement. This review clarifies the main mechanisms by which the immune microenvironment regulates lymph node metastasis in rectal cancer and summarizes the current state of research on imaging-based assessment of immune microenvironment heterogeneity, with a focus on MRI. The objective is to enhance the precision of preoperative diagnosis of lymph node metastasis, improve patient prognosis, and provide novel perspectives for individualized diagnosis and treatment.

[1]
李吉, 陈杨, 张茂镕, 等. 中国常见消化系统恶性肿瘤伤残调整寿命年归因于人口老龄化的比例分析和趋势预测[J]. 实用肿瘤学杂志, 2025, 39(5): 372-380.
[2]
Guan X, Yu G, Zhang W, et al. An easy-to-use artificial intelligence preoperative lymph node metastasis predictor (LN-MASTER) in rectal cancer based on a privacy-preserving computing platform: multicenter retrospective cohort study[J]. Int J Surg, 2023, 109(3): 255-265.
[3]
中国医师协会内镜医师分会腹腔镜外科专业委员会, 中国医师协会结直肠肿瘤专业委员会腹腔镜专业委员会, 中华医学会外科学分会结直肠外科学组,等. 中国直肠癌侧方淋巴结转移诊疗专家共识(2024版)[J]. 消化肿瘤杂志(电子版), 2024, 16(1): 1-16.
[4]
Mroczkowski P, Dziki Ł, Vosikova T, et al. Rectal cancer: are 12 lymph nodes the limit?[J]. Cancers (Basel), 2023, 15(13): 3447.
[5]
王治杰, 刘骞. 直肠和乙状结肠癌区域淋巴结清扫的规范化开展[J]. 中华胃肠外科杂志, 2022, 25(4): 309-314.
[6]
Awiwi MO, Kaur H, Ernst R, et al. Restaging MRI of rectal adenocarcinoma after neoadjuvant chemoradiotherapy: imaging findings and potential pitfalls[J]. Radiographics, 2023, 43(4): e220135.
[7]
Driessen DAJJ, Zámecnik P, Dijkema T, et al. High-accuracy nodal staging of head and neck cancer with USPIO-enhanced MRI: a new reading algorithm based on node-to-node matched histopathology[J]. Invest Radiol, 2022, 57(12): 810-818.
[8]
Yamamoto H. Micrometastasis in lymph nodes of colorectal cancer[J]. Ann Gastroenterol Surg, 2022, 6(4): 466-473.
[9]
Trac N, Chen Z, Oh HS, et al. MRI detection of lymph node metastasis through molecular targeting of C-C chemokine receptor type 2 and monocyte hitchhiking[J]. ACS Nano, 2024,18(3): 2091-2104.
[10]
Harris MA, Savas P, Virassamy B, et al. Towards targeting the breast cancer immune microenvironment[J]. Nat Rev Cancer, 2024, 24(8): 554-577.
[11]
Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives[J]. Mol Cancer, 2021, 20(1): 131.
[12]
Dash P, Yadav V, Das B, et al. Experimental toolkit to study the oncogenic role of WNT signaling in colorectal cancer[J]. Biochim Biophys Acta Rev Cancer, 2025, 1880(4): 189354.
[13]
Wang P, Li G, Sun X, et al. miR-182-5p facilitates colorectal cancer progression through manipulating neurocalcin delta mediated Wnt/β-catenin signalling[J]. Eur J Med Res, 2025, 30(1): 352.
[14]
Matsuoka T, Yashiro M. The role of the transforming growth factor-β signaling pathway in gastrointestinal cancers[J]. Biomolecules, 2023, 13(10): 1551.
[15]
Hsu TH, Chang YC, Lee YY, et al. B4GALT1-dependent galectin-8 binding with TGF-β receptor suppresses colorectal cancer progression and metastasis[J]. Cell Death Dis, 2024, 15(9): 654.
[16]
Xu D, Li M, Ran L, et al. C5aR1 promotes the progression of colorectal cancer by EMT and activating Wnt/β-catenin pathway[J]. Clin Transl Oncol, 2023, 25(2): 440-446.
[17]
Chen Y, Zhao N, Xu L, et al. Integrative multi-omics analysis reveals the LncRNA 60967.1-PLCD4-ATRA axis as a key regulator of colorectal cancer progression and immune response[J]. Mol Cancer, 2025, 24(1): 164.
[18]
Wang C, Liu W, Yang S, et al. BAP31 promotes epithelial-mesenchymal transition progression through the exosomal miR-423-3p/bim axis in colorectal cancer[J]. Int J Mol Sci, 2025, 26(12): 5483.
[19]
Ji H, Hu C, Yang X, et al. Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions[J]. Signal Transduct Target Ther, 2023, 8(1): 367.
[20]
Zhan Y, Huang C, Wang R, et al. N-acetylglucosaminyltransferase V drives colorectal cancer metastasis by facilitating ZO-1 ubiquitination and degradation[J]. Cancer Cell Int, 2024, 24(1): 366.
[21]
Stehr AM, Wang G, Demmler R, et al. Neutrophil extracellular traps drive epithelial-mesenchymal transition of human colon cancer[J]. J Pathol, 2022, 256(4): 455-467.
[22]
Liu X, Li X, Wei H, et al. Mast cells in colorectal cancer tumour progression, angiogenesis, and lymphangiogenesis[J]. Front Immunol, 2023,14: 1209056.
[23]
He Q, Xiang L, Luo Y, et al. Tumor-associated macrophages in colon cancer immunotherapy: mechanisms, natural product interventions, and microenvironment remodeling[J]. Front Immunol, 2025, 16: 1642091.
[24]
Huang Z, Li Y, Qian Y, et al. An LCN2-dependent positive-feedback loop between gastric cancer cells and tumor-associated-macrophages mediates lymphangiogenesis and lymphatic metastasis[J]. Adv Sci (Weinh), 2025, 12(44): e08352.
[25]
曾海伦, 刘星, 唐宇飞, 等. 结肠癌相关性调节性B细胞介导淋巴管生成的体外研究[J]. 中国肿瘤临床, 2023, 50(5): 232-236.
[26]
Liu H, Shi H, Sun Y. Identification of a novel lymphangiogenesis signature associated with immune cell infiltration in colorectal cancer based on bioinformatics analysis[J]. BMC Med Genomics, 2024, 17(1): 2.
[27]
Volk-Draper L, Athaiya S, Espinosa Gonzalez M, et al. Tumor microenvironment restricts IL-10 induced multipotent progenitors to myeloid-lymphatic phenotype[J]. PLoS One, 2024, 19(4): e0298465.
[28]
Gillot L, Baudin L, Rouaud L, et al. The pre-metastatic niche in lymph nodes: formation and characteristics[J]. Cell Mol Life Sci, 2021, 78(16): 5987-6002.
[29]
Wang Y, Lu H, Li M. Expression of PD-L1 and PD-1 in stage T4 rectal cancer tissues and surrounding metastatic lymph nodes and correlation with prognosis[J]. Cell Mol Biol(Noisy-le-grand), 2022, 68(8): 74-78.
[30]
Zhao T, Luo Y, Sun Y, et al. Characterizing macrophage diversity in colorectal malignancies through single-cell genomics[J]. Front Immunol, 2025, 16: 1526668.
[31]
Wang Y, Wang J, Yang C, et al. A study of the correlation between M2 macrophages and lymph node metastasis of colorectal carcinoma[J]. World J Surg Oncol, 2021, 19(1): 91.
[32]
Nie F, Sun X, Sun J, et al. Epithelial-mesenchymal transition in colorectal cancer metastasis and progression: molecular mechanisms and therapeutic strategies[J]. Cell Death Discov, 2025, 11(1): 336.
[33]
Wozniakova M, Skarda J, Raska M. The role of tumor microenvironment and immune response in colorectal cancer development and prognosis[J]. Pathol Oncol Res, 2022, 28: 1610502.
[34]
Huang X, Cai W, Liu L, et al. Low mutation burden and differential tumor-infiltrating immune cells correlate with lymph node metastasis in colorectal cancer[J]. Int J Clin Exp Pathol, 2020, 13(9): 2259-2269.
[35]
吕杨波, 邱丹, 陈震宏. 趋化因子受体表达与结直肠癌淋巴结转移的关系研究[J]. 浙江医学, 2021, 43(12): 1295-1297+1303, 后插3.
[36]
Wang D, Wang X, Song Y, et al. Exosomal miR-146a-5p and miR-155-5p promote CXCL12/CXCR7-induced metastasis of colorectal cancer by crosstalk with cancer-associated fibroblasts[J]. Cell Death Dis, 2022, 13(4): 380.
[37]
Rezzola S, Sigmund EC, Halin C, et al. The lymphatic vasculature: an active and dynamic player in cancer progression[J]. Med Res Rev, 2022, 42(1): 576-614.
[38]
Wang Y, Jia J, Wang F, et al. Pre-metastatic niche: formation, characteristics and therapeutic implication[J]. Signal Transduct Target Ther, 2024, 9(1): 236.
[39]
Jou E, Rodriguez-Rodriguez N, Ferreira AF, et al. An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for Apc mutation-driven intestinal tumorigenesis[J]. Sci Immunol, 2022, 7(72): eabn0175.
[40]
Nie SC, Jing YH, Lu L, et al. Mechanisms of myeloid-derived suppressor cell-mediated immunosuppression in colorectal cancer and related therapies[J]. World J Gastrointest Oncol, 2024, 16(5): 1690-1704.
[41]
Elomaa H, Härkönen J, Väyrynen SA, et al. Quantitative multiplexed analysis of indoleamine 2,3-dioxygenase (ido) and arginase-1 (arg1) expression and myeloid cell infiltration in colorectal cancer[J]. Mod Pathol, 2024, 37(4): 100450.
[42]
Bied M, Ho WW, Ginhoux F, et al. Roles of macrophages in tumor development: a spatiotemporal perspective[J]. Cell Mol Immunol, 2023, 20(9): 983-992.
[43]
Liu J, Zhao L, Wang L, et al. Integrin-mediated timp1 signaling reprograms liver macrophages and accelerates colorectal cancer metastasis[J]. Cells, 2025, 15(1): 29.
[44]
Li S, Fu X, Ning D, et al. Colon cancer exosome-associated HSP90B1 initiates pre-metastatic niche formation in the liver by polarizing M1 macrophage into M2 phenotype[J]. Biol Direct, 2025, 20(1): 52.
[45]
Cousin N, Cap S, Dihr M, et al. Lymphatic PD-L1 expression restricts tumor-specific CD8+ T-cell responses[J]. Cancer Res, 2021, 81(15): 4133-4144.
[46]
Li CY, Park HJ, Shin J, et al. Tumor-associated lymphatics upregulate MHC-Ⅱ to suppress tumor-infiltrating lymphocytes[J]. Int J Mol Sci, 2022, 23(21): 13470.
[47]
Lau D, Corrie PG, Gallagher FA. MRI techniques for immunotherapy monitoring[J]. J Immunother Cancer, 2022, 10(9): e004708.
[48]
Khalili N, Kazerooni AF, Familiar A, et al. Radiomics for characterization of the glioma immune microenvironment[J]. NPJ Precis Oncol, 2023, 7(1): 59.
[49]
戎泽宁, 蔡崇鹏, 李梦蕾, 等. 影像组学在评估肿瘤免疫微环境中的应用及价值[J]. 中华放射学杂志, 2022, 56(11): 1276-1279.
[50]
Zhao R, Shen W, Zhao W, et al. Integrating radiomics, pathomics, and biopsy-adapted immunoscore for predicting distant metastasis in locally advanced rectal cancer[J]. ESMO Open, 2025, 10(3): 104102.
[51]
Li S, Dai Y, Chen J, et al. MRI-based habitat imaging in cancer treatment: current technology, applications, and challenges[J]. Cancer Imaging, 2024, 24(1): 107.
[52]
Zhang J, Tian F, Shang Y, et al. MRI-guided risk stratification for neoadjuvant immunotherapy in rectal cancer[J]. Front Immunol, 2026, 17: 1782231.
[53]
Xu L, Sun L, Fu Y, et al. Diagnostic accuracy and pitfalls of MRI for restaging locally advanced rectal cancer in patients following anti-PD1 therapy plus neoadjuvant chemoradiotherapy: a multicenter study[J]. Abdom Radiol (NY), 2026, 51(1): 14-25.
[54]
张岚, 周彦汝, 韩鼎盛, 等. 基于MRI影像组学构建PD-1/PD-L1抑制剂治疗dMMR/MSI-H直肠癌疗效的预测模型[J]. 中国医学计算机成像杂志, 2024, 30(3): 343-348.
[55]
张晓燕, 朱海涛, 李晓婷, 等. 基于MRI影像组学构建程序性死亡蛋白-1抗体联合全程新辅助放化疗后局部进展期直肠癌病理完全缓解的预测模型[J]. 中华胃肠外科杂志, 2022, 25(3): 228-234.
[56]
Liu S, Zhang Y, Lin Y, et al. Case report: The MSI-L/p-MMR metastatic rectal cancer patient who failed systemic therapy responds to anti-PD-1 immunotherapy after stereotactic body radiation-therapy[J]. Front Immunol, 2022, 13: 981527.
[57]
李文亮, 乔艳萍, 娄彦昂, 等. 基于CT影像组学特征预测结直肠癌患者PD-L1表达水平的研究[J]. 临床医学进展, 2024, 14(12): 158-169.
[58]
Rifi AL, Raets C, Dufait I, et al. Integrating radiomics and immunology: non-invasive assessment of intratumoral CD8+ T cell levels in murine models[J]. Comput Biol Med, 2025,190: 110061.
[59]
Jeon SH, Lim YJ, Koh J, et al. A radiomic signature model to predict the chemoradiation-induced alteration in tumor-infiltrating CD8+ cells in locally advanced rectal cancer[J]. Radiother Oncol, 2021, 162: 124-131.
[60]
Ma W, Hou C, Yang M, et al. Different MRI-based radiomics machine learning models to predict CD3+ tumor-infiltrating lymphocytes in rectal cancer[J]. Front Oncol, 2025, 15: 1509207.
[61]
Xue K, Liu L, Liu Y, et al. Radiomics model based on multi-sequence MR images for predicting preoperative immunoscore in rectal cancer[J]. Radiol Med, 2022, 127(7): 702-713.
[62]
Hoffmann E, Masthoff M, Kunz Wg, et al. Multiparametric MRI for characterization of the tumour microenvironment[J]. Nat Rev Clin Oncol, 2024, 21(6): 428-448.
[63]
Tian N, Wang Q, Lv Y, et al. Mature tertiary lymphoid structures support B cell-mediated antitumour immunity and are disrupted by neoadjuvant therapy in rectal cancer: a multicentre, retrospective study[J]. EBioMedicine, 2025, 122: 106030.
[64]
Yang H, Wong C, Liang W, et al. A noninvasive AI model based on multi-dimensional MRI features for predicting tertiary lymphoid structures, immunotherapy response, and prognosis in rectal cancer[J]. Int J Surg, 2026, 112(2): 4317-4328.
[65]
Yue H, Geng J, Gong L, et al. Radiation hematologic toxicity prediction for locally advanced rectal cancer using dosimetric and radiomics features[J]. Med Phys, 2023, 50(8): 4993-5001.
[66]
Kuncman Ł, Stawiski K, Masłowski M, et al. Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer[J]. Strahlenther Onkol, 2020, 196(11): 998-1005.
[67]
刘晓冬, 刘爱连, 李烨, 等. DCE-MRI及IVIM模型在直肠癌病理分级中的应用及其灌注参数的相关性[J]. 中国医学影像学杂志, 2020, 28(4): 256-259+268.
[68]
Zhang X, Liu S, Zhao X, et al. Magnetic resonance imaging-based radiomic features for extrapolating infiltration levels of immune cells in lower-grade gliomas[J]. Strahlenther Onkol, 2020, 196(10): 913-921.
[69]
Hectors SJ, Lewis S, Besa C, et al. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma[J]. Eur Radiol, 2020, 30(7): 3759-3769.
[70]
Wang Y, Xie B, Wang K, et al. Multi-parametric MRI habitat radiomics based on interpretable machine learning for preoperative assessment of microsatellite instability in rectal cancer[J]. Acad Radiol, 2025, 32(7): 3975-3988.
[71]
Hu S, Xing X, Liu J, et al. Correlation between apparent diffusion coefficient and tumor-stroma ratio in hybrid 18F-FDG PET/MRI: preliminary results of a rectal cancer cohort study[J]. Quant Imaging Med Surg, 2022, 12(8): 4213-4225.
[72]
Cai C, Hu T, Gong J, et al. Multiparametric MRI-based radiomics signature for preoperative estimation of tumor-stroma ratio in rectal cancer[J]. Eur Radiol, 2021, 31(5): 3326-3335.
[73]
Yuan J, Sun Y, Liu K, et al. Advanced diffusion-weighted imaging biomarkers for non-invasive assessment of tumor microenvironment in rectal cancer: restricted spectrum imaging[J]. Abdom Radiol(NY), 2025, 50(9): 3917-3927.
[74]
Kastinen M, Härkönen J, Sirniö P, et al. Unraveling the effects and characteristics of proliferating tumor and cytotoxic T cells in colorectal cancer[J]. Clin Cancer Res, 2026, 32(2): 350-362.
[75]
Malviya G, Lannagan TRM, Johnson E, et al. Noninvasive stratification of colon cancer by multiplex PET imaging[J]. Clin Cancer Res, 2024, 30(8): 1518-1529.
[76]
Lu ZR, Laney V, Li Y. Targeted contrast agents for magnetic resonance molecular imaging of cancer[J]. Acc Chem Res, 2022, 55(19): 2833-2847.
[77]
Wu Y, Shang J, Zhang X, et al. Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review[J]. J Nanobiotechnology, 2024, 22(1): 783.
[78]
Fu X, Cai Z, Fu S, et al. Boronic acid group modified Mn-porphyrin nanoparticles evade macrophage uptake for lymph node metastasis diagnosis via MRI[J]. Biomaterials, 2026, 330: 124023.
[79]
van de Donk PP, Oosting SF, Knapen DG, et al. Molecular imaging to support cancer immunotherapy[J]. J Immunother Cancer, 2022, 10(8): e004949.
[80]
Lauwers Y, De Groof TWM, Vincke C, et al. Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer[J]. Proc Natl Acad Sci USA, 2024, 121(52): e2409668121.
[1] 鲁峰刚, 刘宇, 张毅, 王秦玉. 新辅助放化疗直肠癌根治术患者术后吻合口漏影响因素分析及风险预测模型构建[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(04): 347-351.
[2] 朱东熙, 李锴文, 何旺. 广东省医学会泌尿外科疑难病例多学科会诊(第29期)——膀胱癌保膀胱综合治疗后进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(03): 352-357.
[3] 陈嘉林, 余绍辉, 李如春, 周太成. 基于倾向得分匹配法研究内脏脂肪面积与结直肠癌术后切口疝的相关性[J/OL]. 中华疝和腹壁外科杂志(电子版), 2026, 20(04): 379-385.
[4] 徐正, 杨明, 张岳阳, 周海涛, 关旭, 王锡山. 2024年与2022年中国结直肠癌发病和死亡估计值的描述性比较[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(04): 315-320.
[5] 高韶华, 徐涛, 宋亮, 雷丽, 王洪伟, 刘宏新. 1994—2023年中国结直肠癌疾病年龄-时期-队列效应及危险因素归因分析——基于GBD 2023研究[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(04): 321-330.
[6] 金磊, 印小毛, 李新星, 胡志前. 大肠黏液腺癌的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(04): 299-306.
[7] 张若昕, 陆瑶, 刘益磊, 陈国良, 张剑. 盆腔脏器联合切除术中的ERAS与PROMs:从医生视角到患者视角的转变[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(04): 307-314.
[8] 孟春孜, 章群, 钱晓萍. 晚期结直肠癌三线免疫联合方案与单药化疗或单药靶向治疗的疗效对比Meta分析[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(03): 215-223.
[9] 贾宇飞, 王哲学, 王飞, 蔡昂书, 姚占胜. 中性粒细胞与淋巴细胞比值(NLR)和结直肠癌幸存者全因死亡的关联研究:基于NHANES 1999—2018数据的分析[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(03): 224-231.
[10] 黄子强, 马晓璐, 沈浮, 王颢, 邵成伟, 张卫, 陆建平, 陆海迪. 基于磁共振成像的深度学习方法在直肠癌术前TN分期中的应用研究[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(03): 232-243.
[11] 秦松涵, 王继伟, 张桃, 谢铭. 自噬在结直肠癌发生与发展中的作用及研究进展[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(03): 263-268.
[12] 张瑞豪, 李文星. 肠道微生物组在结直肠癌化疗中的双向调控作用[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(03): 269-273.
[13] 傅书强, 王宏刚. 液体活检主要生物标志物在结直肠癌中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(03): 274-281.
[14] 张婧萱, 郭佳星, 李紫红, 陈怡颖, 乔媛, 宝莹娜. 多线治疗失败后31例复发转移性结直肠癌局部挽救性放射治疗的研究[J/OL]. 中华消化病与影像杂志(电子版), 2026, 16(03): 206-211.
[15] 董妮, 肖康, 王齐成. 经直肠超声多参数联合检测对中低位直肠癌淋巴结转移的术前预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2026, 16(03): 212-215.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?